Regional gene therapy for cancer Book Section
| Authors: | Cherkassky, L.; Grosser, R.; Adusumilli, P. S. |
| Editors: | Fong, Y.; Gamblin, T. C.; Han, E. S.; Lee, B.; Zager, J. S. |
| Article/Chapter Title: | Regional gene therapy for cancer |
| Abstract: | Two successful regional gene therapies have emerged in recent years: chimeric antigen receptor (CAR) T-cell therapy and oncolytic virus therapy. Coupled with the recent advances in the understanding of solid tumor immunology, the success of these therapies illustrates how regional therapy can be combined with efficient gene transfer and immune stimulation to treat solid tumors. CAR T cells and oncolytic viruses leverage the fundamental advantages of regional deliveryto accomplish the following three objectives: 1. Enhance delivery of therapeutics to the tumor. Cancer-targeted gene therapy can be inefficient when infused intravenously, owing to the increased volume of distribution, sequestration in other organs, and poor or altered vascularity, which limit drug perfusion into tumor tissue. Regional CAR T-cell administration can bypass these limitations. Oncolytic viruses can be regionally infused or intralesionally injected. 2. Enhance targeting of cancer cells, thereby limiting normal-tissue toxicity. CAR T cells and oncolytic viruses are genetically modified to optimize cancer-specific targeting. The flexibility afforded by genetic engineering allows preferential targeting, infection of cancer cells, and sparing of normal tissues. 3. Generate both a local and a systemic immune response that can target metastatic disease and prevent tumor recurrence. Perhaps, the most impressive feature of these local therapies is their ability to generate an immune response that extends beyond the primary tumor to establish systemic immune surveillance. This immune response follows the tenets of the adaptive immune system: it establishes circulating immune memory that is capable of self-renewal and is long-lasting. Regional delivery of CAR T cells elicits a robust local immuneresponse and establishes systemic immunity. Oncolytic viruses not only target tumors via local cancer cell destructionbut also generate a local and systemic immune response. The regression of metastatic lesions following local delivery ofoncolytic virus exemplifies the potential to generate systemic immune responses. In this chapter, we highlight the principles of regional delivery of gene therapies, detail how genetic engineering can be used to specifically target tumor tissue and enhance efficacy and illustrate the uniquely powerful response that can be gained when the immune system is directed to target solid tumors. We also examine the technologies supporting regional delivery and discuss how existing infusion practices are used to treat solid tumors. © Springer Nature Switzerland AG 2020. All rights reserved. |
| Keywords: | immunotherapy; gene therapy; oncolytic virus; chimeric antigen receptor; t-cell therapy; regional delivery |
| Book Title: | Cancer Regional Therapy: HAI, HIPEC, HILP, ILI, PIPAC and Beyond |
| ISBN: | 978-3-030-28890-7 |
| Publisher: | Springer Nature Switzerland Ag |
| Publication Place: | Cham, Switzerland |
| Date Published: | 2020-01-01 |
| Start Page: | 55 |
| End Page: | 71 |
| Language: | English |
| DOI: | 10.1007/978-3-030-28891-4_5 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Book Chapter: 5 -- Export Date: 3 August 2020 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
-
496Adusumilli -
14Cherkassky -
9
Grosser
Related MSK Work